Integration of perioperative features and intragraft TCF7L2 expression to predict lipid metabolic disorder in liver transplant recipients

作     者：Junbin Zhou Rongli Wei Guanghan Fan Zhengxing Lian Xuanyu Zhang Linsong Tang Zhetuo Qi Haiyang Xie Shusen Zheng Qiang Wei Xiao Xu 

作者机构：Department of Hepatobiliary and Pancreatic SurgeryPeople’s Hospital of LishuiAffiliated Lishui Hospital of Wenzhou Medical UniversityThe First Affiliated Hospital of Lishui UniversityLishui 323000China NHFPC Key Laboratory of Combined Multi-Organ TransplantationHangzhou 310003China Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang ProvinceDepartment of Hepatobiliary and Pancreatic SurgeryHangzhou First People’s HospitalHangzhou 310006China Department of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of UrologyThe Second Affiliated HospitalZhejiang University School of MedicineHangzhou 310009China Department of Hepatobiliary and Pancreatic SurgeryDepartment of Liver TransplantationShulan(Hangzhou)HospitalHangzhou 310011China Hangzhou Medical CollegeHangzhou 310059China Zhejiang University School of MedicineHangzhou 310058China 

出 版 物：《Science China(Life Sciences)》 (中国科学(生命科学英文版))

年 卷 期：2025年第68卷第1期

页      面：297-299页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the Medical and Health Technology Program in Zhejiang Province(WKJ-ZJ-2120) the National Key Research and Development Program of China(2021YFA1100500) Major Research Plan of the National Natural Science Foundation of China(92159202) Public Welfare Technology Application Research Project of Lishui City(2023SJZC110) 

主　　题：liver graft 

摘      要：Dear Editor,Liver transplantation(LT)is the only curative therapy for patients with endstage liver disease(He et al.,2023;Ling et al.,2022).Post-transplant hypertriglyceridemia(PTHT),which has an incidence of up to 32.8%in 6 months after LT,is one of the major post-transplant complications(Toshima et al.,2020).With the prolongation of the recipient’s survival time,the incidence of PTHT is increasing,becoming an important factor that affects the recipient’s quality of life and survival *** with various metabolic complications,including PTHT,have a 1.78 times higher risk of atherosclerotic cardiovascular disease(ASCVD)development and death than recipients without these complications(Jiménez Pérez et al.,2016).Studies have shown that PTHT,accompanied by other posttransplant metabolic complications and immunosuppressants,are important risk factors for post-transplant ASCVD and mediate 19%–42% of nongraft-related deaths(Davis and Shadab Siddiqui,2017;Jiménez-Pérez et al.,2016).However,early prediction of PTHT remains a major challenge.